The effect of an anti-VEGF drug on proliferative diabetic retinopathy complicated with diabetic macular edema
Not Applicable
Suspended
- Conditions
- proliferative diabetic retinopathy complicated with diabetic macular edema
- Registration Number
- JPRN-UMIN000027618
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
In case of receiving intravitreal administration of anti-VEGF drug within 3 months before enrollment. When panretinal or partial retinal photocoagulation was performed for the purpose of treatment against diabetic retinopathy within 3 months before starting participation. During systemic administration of anti-VEGF drug. Pregnant women or potential patients. Patients judged inappropriate as subjects by research managers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method retinal nonperfusion area in fluorescein fundus angiography after administration of aflibercept
- Secondary Outcome Measures
Name Time Method best corrected visual acuity, macular retinal thickness measured by optical coherence tomography, number of retinal neovasculature, grade of neovascularization on the optic nerve head, grade of neovascularization on the iris